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Antisense oligonucleotides directed against p53 have antiproliferative
effects unrelated to effects on p53 expression
CM Barton and NR Lemoine
Molecular Pathology Laboratorn, Imperial Cancer Research Fund Oncology Unit, Hammersmith Hospital, Du Cane Road,
London W12 ONN, L'K.
Smary Antisense oligonucleotides targeting p53 have been hailed as a potentially new technique for
treating patients with cancer, and there have been encouraging reports of good patient tolerance in vivo and of
antiproliferative effects in vitro. However, evidence is lacking that these oligonucleotides are acting via an
antisense interaction to modulate p53 expression. We examined a phosphorothioate antisense oligonucleotide,
directed against exon 10 of the TP53 gene, and a chimaeric phosphorothioate-phosphodiester oligonucleotide
directed against the p53 translation initiation codon. Both failed to specifically suppress p53 protein produc-
tion in a cell-free assay system or to have any effect on mutant p53 expression by human pancreatic cancer cell
lines. Antiproliferative effects were apparent, especially with the phosphorothioate antisense oligonucleotide,
but this was independent of the p53 status of the cells (mutant, wild-type or absent) and also occurred with the
control (sense and randomised) oligonucleotides. The most dramatic antiproliferative effects were seen with the
.control' phosphorothioate oligonucleotides. These findings suggest that the antiproliferative effects of some
antisense oligonucleotides may be unrelated to expression of the gene they have been designed to target.
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Modulation of gene expression by naturally occurring anti-
sense interactions is well documented in prokaryotes and
may occur naturally in eukaryotic cells (reviewed in Murray
and Crockett, 1992; Thomas, 1992; Nellen and Lichtenstein,
1993). Antisense techniques have also been devised to selec-
tively reduce gene expression by the sequence-specific binding
of complementary nucleic acids. Such techniques have
become powerful tools for selectively reducing the expression
of target genes in vitro, and there is increasing interest in the
possibility of using the same technology in vivo for
therapeutic purposes.
The antisense oligonucleotide approach involves the
exogenous administration of short, synthetic, single-stranded
oligonucleotide sequences, generally DNA based, which are
taken up relatively inefficiently by the cell and released into
the cytoplasm. They are thought to act predominantly by
blocking translation of mRNA (reviewed in Murray and
Crockett, 1992; Toulme, 1992; Carter and Lemoine, 1993;
Nellen and Lichtenstein, 1993; Prins et al., 1993). Sequences
complementary to the protein-coding part of the mRNA are
thought to act mainly by causing cleavage by RNAse H,
which specifically degrades the RNA component of
RNA-DNA hybrids. Sequences which target the 5' untrans-
lated region are thought to prevent attachment and sliding of
the 40S ribosomal subunit by steric hindrance, and those
which bind close to the AUG initiation codon may prevent
further assembly of the translation initiation complex.
Most work has been done with oligonucleotides modified
to increase their stability and lipid solubility, for example by
replacement of the phosphodiester linkage in the sugar-
phosphate backbone to increase nuclease resistance. A phos-
phorothiorate linkage (in which the oxygen atom is replaced
by a sulphur atom) is a commonly used modification.
Chimaeric oligonucleotides have the modified linkage for
only part of the molecule, usually the 5' and 3' ends, since
intracellular degradation is mainly due to exonucleases (Giles
and Tidd, 1992; Ortigao et al., 1992; Toulme, 1992).
TP53 is an attractive target for an antisense approach in
human cancer for several reasons. Although classified as a
tumour-suppressor gene, the mutant forms commonly found
in human tumours have many of the features associated with
a dominant oncogene, including transforming activity
(Parada et al., 1984). TP53 is the most frequent gene to be
mutated in human cancer, and expression of mutant p53 is
thought to be important in a wide range of tumours, includ-
ing many that are primarily resistant to conventional forms
of therapy (Nigro et al., 1989; Levine, 1992; Levine et al.,
1994). Wild-type p53 is dispensable for normal cell growth
and metabolism, albeit at the cost of an increased suscep-
tibility to malignant change (Malkin et al., 1990; Srivastava
et al., 1990; Donehower et al., 1992; Harvey et al., 1993).
There is also evidence for a gene dosage effect so that com-
plete suppression of mutant p53 expression may not be
necessary for a significant anti-tumour effect, especially if
there is some residual wild-type gene expression (Schafer et
al., 1994). Lastly, there is evidence that p53 expression may
be modulated naturally by the endogenous production of
antisense RNA transcripts (Khochbin et al., 1992).
Phosphorothiate oligonucleotides have now been given
systemically to animals and humans (Iversen et al., 1992;
Spinolo et al., 1992a). In a phase I clinical trial a phos-
phorothioate oligonucleotide targeting p53 exon 10, OL(1)
p53, was given by continuous infusion for up to 10 days and
was well tolerated with few adverse effects (Spinolo et al.,
1992b, Bishop et al., 1993; Bayever et al., 1993, 1994). This
oligonucleotide has been reported to have a significant anti-
proliferative effect on AML (Bayever et al., 1994) and pan-
creatic cancer cells (Bayever and Haines, 1993) in vitro, and,
when given by systemic infusion to patients, to inhibit the
growth of their leukaemic blasts in vitro (Spinolo et al.,
1992b; Bishop et al., 1993; Bayever et al., 1993, 1994).
Exciting as these reports are, no evidence has been provided
that the oligonucleotide is acting via an antisense interaction
or that it modulates p53 expression. We have investigated
this oligonucleotide in pancreatic cancer cell lines, since ex-
pression of mutant p53 is thought to be an important early
event in pancreatic carcinogenesis (Barton et al., 1991; Wylie
et al., 1993) and because pancreatic cancer is notoriously
resistant to currently available cancer therapies (Alanen and
Joensuu, 1993; Ellis and Cunningham, 1994). For com-
parison, we have also investigated a chimaeric phosphoro-
thioate-phosphodiester antisense oligonucleotide which
targets a different region of p53 mRNA, the initiation codon.
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This oligonucleotide has been reported to reduce p53 expres-
sion and alter prolferation in vitro in chronic myeloid
leukaemia (CML) cells (Bi et al., 1994).
Misteals ald i
Cells
Six pancreatic cell nes were studied, three ofwhich (PANC-
1, AsPC-1, CaPan-2) were obtained from the American Type
Culture Collection (ATCC) and three from original sources.
PT45 and 818.4 were gifts from Dr H Kalthoff and Dr W
Schmiegel (Department of Immunology, University Hospital
Eppendorf, Hamburg, Germany) and Colo-357 from Dr G
Morgan (Surgical Division, Denver, CO, USA). Cells were
cultured in RPMI-1640 or Dulbecco's modifid Eagle
medium (DMEM) supplemented with 10% heat-inactivated
(65-C for 30min) fetal calf serum (FCS) and antibiotics.
Media were supplied by ICRF Media Production and serum
obtained from Life Technologies.
Antisense oligonucleotides
Six antisense oligonucleotides were synthesised and purified
by high-performance liquid chromatography at the ICRF
Oligonculeotide Synthesis Laboratory, Clare Hall. On
receipt, they were double washed with 70% ethanol, briefly
air dried and resuspended in sterile RPMI-1640 to a final
concentration of 100iLM. After checking the concentration by
spectrophotometry, they were stored in aliquots at -20'C.
The antisense oligonucleotide OLlp53as (corresponding to
A-ODN or OL(l)p53 in other reports) is complementary to a
region within exon 10 of the TP53 gene, and the phos-
phodiester backbone is replaced throughout with a phos-
phorothioate linkage (Spinolo et al., 1992b; Bayever and
Haines 1993; Bishop et al., 1993; Bayever et al., 1993, 1994).
Two control oligonucleofides were selected for OLlp53as:
OLlp53s, which is complementary to OLlp53as, and
OLlpS3rand, in which the OLlp53as sequence is randomised
Both control oligonucleotides were synthesised with phos-
phorothioate finkages throughout (indicated by underlining).
OLlp53as CCCTGCTCCCCCCTGGCTCC
OLlp53s GGAGCCAGGGGGGAGCAGGG
OLlpS3rand GGCCCC-TCCTCCTCGCCCC
The antisense olgonucleotide Bip53as is complementary to
the 18 nucleotides flanking and including the TP53 ATG
initiation codon and the phosphodiester backbone is replaed
by phosphorothioate links between the first four and last
four nucleotides to improve stability (Bi et al., 1994). Two
control oligonucleotides were selected for Bip53as; Bip53s,
which is complementary to Bip53as, and Bip53rand, in which
the sequence Bip53as is randomised. Both control oligo-
nucleotides have the same chimaeric structure with three
phosphothiate linis between the first four and last four
nucleotides (indicated by underlining).
Bip53as CGGCTCCTCCATGGCAGT
Bip53s ACTGCCATGGAGGAGCCG
Bip53rand GCCTCCGGCCTTAGACTG
The oligonucleotide sequences were checked for predicted
secondary structure by direct scrutiny and by computer
simulation. Bip53as, Bip53s, OLlp53as and OLlp53s were all
predi to form stems of two nucleotides and Bip53rand
and OLlp53rand were predicted to form a stem of three
nucleotides (CGG). All were checked for matches and coi-
plementarity to other hmnan genetic sequences. Signiant
compkmentarity was found with sveral other proliferation
and differentiation-related genes [for example OLlp53as and
granulocyte-macrophage colony-stimulating factor (GM-
CSF) receptor A-chain mRNA; OLlp53s and human platelet-
derived growth factor A; and integrin z-3 chain mRNAJ. No
significnt compkmentarity was detected twn the control
oligonucleotides Bip53s, Bip53rand, OLlp53s and OLI-
p53rand and TP53, TP53 cDNA or the transcription factor
AP2 cDNA. However, when the sequence offirefly huciferase
was checked for fortuitous complementarity with the
oligonucleotides used, significnt complemntarity was found
in some instances. Bip53as had no significant comple-
mentarity with firefly luciferase, Bip53s had one region of
complementarity starting at codon 1946 (11-18 bp) and
Bip53rand had five regions of complementarity starting at
codons 17 (10-18 bp), 1481 (12-18 bp), 1658 (12-18 bp),
1745 (12-18bp) and 2129 (11-18bp). OLlp53as was com-
plementary to one region starting at codon 1423 (12-20 bp),
OLlp53s was complementary to one region (11-20 bp) start-
ing at codon 401 and OLlp53rand showed significant com-
pleientarity to four regions starting at codons 355
(9-20 bp), 1785 (11-20 bp), 1952 (10-20 bp) and 2134
(10-20bp). The sequences of the SP6 and T7 promoters
were also checked for complementarity with the six oligo-
nudeotides and no signifint complementarity was found.
To verify that the antisense oligonucleotides selected were
capable of binding their putative target sequences, at least in
DNA form, PCR amplifications were performed using the
pSP65p53 plasmid (kindly supplied by Dr T Crooke, Ludwig
Institute for Cancer Research, St Mary's Hospital Medical
SchooL London, UK) as template. Polymerase chain reaction
(PCR) with primer pairs Bip53s and OLlp53as or Bip53as
and OLlp53s reliably produced the 1007 bp predicted pro-
duct using a variety of PCR conditions (data not shown).
The CellTiter 96 non-radioactive cellproliferation/cytotoxicity
assay (MTTassay)
The Promega CellTiter 96 non-radioactive cell proliferation/
cytotoxcity assay (MiT assay), was performed according to
the manufacturer's instructions, as follows. A cell suspension
was prepared from cells growing in standard tissue culture
dishes by trypsin/versene treatment. Cells were counted and
the suspension adjusted to give 1-2 x 105ml-l then l00pl
was placed in each well of replicate 96-well cultum dishes in
the presence of different concentrations (0.5 FM, 1 JM, 5 FM
and IO M) of antisense and control oligonucleotides. MNT
assays were performed after 24, 48 and 72 h growth. Fifty
microltres of MTT dye solution was added to each well and
the plates retuned to the 37C incubator for 4 h. The 100pl
of solubiuisation solution was added to each well and incuba-
tion continued for another hour. The contents of each well
were mixed briefly using a multichannel pipett and the
absorbance measured on an enzyme-linked immunosorbent
assay (ELISA) plate reader (Titertek Multiskan MCC/340) at
a wavelength of 540nm. Each assay was performed in a
multiple of 8 and the results averaged.
p53 EIISA assay
A quantitative measure ofp53 expression was obtained using
a recently developed ELISA assay (Vojtesek et al., 1993).
Initially cells were made quiescent by growing in serum-
deficient (0.5% FCS) medium overnight Then the medium
was changed to incorporate 10% FCS and different concen-
trations of oligonucleotide. Later experiments were per-
formed with cells plated out directly into standard (10%
FCS) medium containing different concentrations of oligo-
nucleotides. After various time periods, the cells were lysed
on ice in a buffer containing 150mM sodium chloride, 50 mM
Tris pH 7.4, 5 mM EDTA, 1% NP-40, 1 mM phenylmethyl-
sulphonyl fluoride (PMSF), 0.5 mM dithiothreitol (DTI),
aprotinin 10 ng ml-' and leupeptin l0ngml-'. Cell extracts
were centrifuged at 100000g for 30 min and the pellets
discarded. The protein content of the supernatants was
measured using the BCA protein assay kit (Pierc) according
to the manufacturer's instructions. Superatants were stored
at -20'C before use.
Meanwhile, Falcon 96-well microtitre plates were incu-
bated overnight at room temperature in a humid chamber
with 50 l per well of antibody DO-7 (Novocastra), diluted
1:500 in phosphate-buffered saline (PBS). Plates were washed
with PBS and blocked for 2 h with 200#1 ofPBS/3% bovine
serum albumin (BSA) at room temperature, then rinsed againA~mf dpd- "Wa- p53
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with PBS. Fifty microlitres of cytosol extract was added to
each antibody-coated well and incubated for 3 h at 4C.
Plates were washed with PBS and 50p11 of the second anti-
body, CM-1 (Novocastra) diluted 1:1000 in PBS/1% BSA,
was added to each well. Plates were incubated for 2 h at 4C,
washed with PBS and peroxida-conjugated swine anti-
rabbit antiserum (Dako), diluted 1:500 in PBS/1% BSA, was
added,50 1 per well. After 2 h incubation at 4-C and a final
wash with PBS, bound enzyme activity was detected as fol-
lows. A fresh solution of o-phenyleediamine and hydrogen
peroxide was made up in 50mM sodium phosphate buffer,
pH 6.0 (2 mg of o-phenylenediamine and Ipl of hydrogen
peroxide per ml of sodium phosphate buffer). One hundred
microlitres of this was added to each well and the reaction
monitored for 5-20 min at room temperature then stopped
with the addition of100 p1 of1 M(N) hydrochloric acid. The
absorbance was measured on an ELISA plate reader at a
wavelength of 492 um. All assays were performed in quad-
ruplicate.
To calibrate, 12 serial dilutions (ranging from 1 to
lOOngml-') of purified soluble recombinant p53 protein
(kindly supplied by Dr A Coffer, Protein Isolation and Clon-
ing Laboratory, ICRF, Lincoln's Inn Fidds, London, UK)
were run with every experiment. Control assays were also
performed on each occasion with no p53 protein(Iysis buffer
only), no DO-7 antibody, no CM-1 antibody and no
peroxidase-conjugated swine antirabbit antiserum so that
background non-specific reactivity could be accounted for.
In vitro transcription/translation assay
In vitro transcription/translation assays were performed ug
a Promega TNT coupled reticulocyte lysate system according
to the manufacturer's instructions. Briefly a master mix was
made up on ice containing TNT rabbit reticulocyte lysate
(12.5 p1 per sample), TNT reaction buffer (1 p1), TNT SP6
RNA polymerase or TNT V7 RNA polymerase (0.5 p1l),
1 mM amino acid mixture minus methionine (0.5 p1), RNasin
ribonuclease inhibitor (0.5 p1) and [GE_S3S L-methionme (2 p1).
The mixture was added to 500 ng of DNA template with or
without the appropriate olgonucleotide and diethylpyrocar-
bonate (DEPC)-treated water to a final volume of 25p1. The
reaction mix was the incubated at 30-C for 1-2 h. An
aliquot was mixed with an equal vohlume of 2 x sample
loading buffer and boied for 2 mm to denature the protein.
Six microlitres of each sample was electrophoresed on a 10%
denaturing polyacrylamide (acrylamide-bisacrylamide, 29:1)
gel overnight at a constant current of 3.5 mA. The gel was to
cut to size, fixed, soaked in Amplify (Amersham Interna-
tional), dried and exposed to radiographic film for 2-6 h.
Three plasmids were used as template. The plasmid
pSP65p53 has full-length wild-type TP53 cDNA cloned
downstream to an SP6 RNA polymerase promoter. In addi-
tion to full-length p53 protein, in vitro transcription/
translation is known to produce a 46 kDa protein as a result
of translation initiation at the methionine residue at
nucleotide 332 and other smaler internally initiated peptides
(Harlow et al., 1985). The plasmid T7PAP2, kindly suppled
by Dr Juha Bosher (ICRF Oncology Unit, Hammrsmith
HospitaL London, UK), has the cDNA for transcription
factor AP2 cloned downstream of a V7 promoter. In vitro
transcription/translation of this construct produces a 46 kDa
protein. In vitro transcription/translation of luciferase tem-
plate DNA, supplied with the kit, was used as a positive
control and produces a 61 kDa protein. Every experiment
included a negative control without template DNA.
Resds
Morphological effects ofoligoucleotide treatment
Six pancreatic cancer cell lines were seleted for analysis.
Two express mutant p53 (PANC-1, PI45), two express wild-
type p53 (Colo-357 and 818.4) and two express no p53
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Fugwe 1 Non-specific toxicity of the OLlp53s (sense control)
oligonucleotide on pancreatic cell lines. The cell line 818.4, which
expreses wild-typc p53 after 48 h growth (a) without added
oligonucetide, (b) in the presence of OLlp53s at 1 ism concen-
tration and (c) in the presence ofOLlp53s at 5pm concentration.
All the cell lines tested showed the same morphological changes
although to slightly different extents, and the other control
oligonuKleotide OLlpS3rand had the same effect at higher doses.
Magniiation x 10.
(AsPC-l and CaPan-2) (Barton et al., 1991; Ruggeri et al.,
1992; Kalthoff et al., 1993; Simon et al., 1994; Berrozpe et
al., 1994). Each was treated with two anisense oligonucleo-
tides, Bip53as and OLlp53as, which target the AUG initia-
tion codon and exon 10 ofp53 mRNA respectively. Each cell
ine -was also treated with sense and sequence-randomised
controls (BipS3s, Bip53rand, OLlpS3s and OLlp53rand
respectively). Four different oligonucleotide concentrations
(0.5piM, 1pM, 5pm, 10IpM) were used.
Within 24 h of exposure to the oligonucleotides profound
morphological changes were noted in cells growing in
OLlp53s (Figure 1). To a lesser extent the same mor-
phological changes were seen in cells growing in the presence
of OLlpS3rand, although at 0.5pM concentration of
OLlp53rand the cells appeared relatively unharmed. All cell
lnes were affected regardle of TP53 status, although to
slightly different extents, and the effects were obviously dose
related and became more noticeable as time went on. The
cells clumpe together, rounded up and lost attachment to
the tissue culture dishes and there were fewer cells present (asAiSOm nIgmjjmds agaWp53
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reflected in the MTT findings). However, many of the
'rounded-up' cells appeared still to be viable since they could
be re-established in culture after removal from the
oligonucleotide solution and washing.
These morphological effects were consistently seen in all
the cell lines being prepared for MTI assay but not in cells
being prepared for ELISAs. Cells for ELISAs were grown for
. IT WrA_=_
16 h in serum-deficient (0.5% FCS) culture medium and were
fully attached to the culture dishes before the oligonucleotide
was added, whereas the cells for MTI assay were plated out
directly into medium containing the oligonucleotides, having
been removed from large culture dishes by standard versene/
trypsin treatment. Others have observed that the effects of
oligonucleotide administration may vary depending on how
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Figwe 2 Effect of antisense and control oligonucleotides on cell proliferation/cytotoxicity in a cell line expressing mutant p53
(P1T45). Cells were grown continuously in the presence of oligonucleotide and MNT assays were performed at 24, 48 and 72 h. For
this cell line six graphs are given showing the effects of four different concentrations of oligonucleotide on cell growth. For clarity,
error bars are omitted on all but the 'no oligonucleotide' control curves. Very similar results were obtained with five other cell lines:
PANC-1 (mutant p53), Colo-357 and 818.4 (wild-type p53) as well as AsPC-1 and CaPan-2 (no p53).
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72long after cell passage the oligonucleotides are added (H
Kalthoff, personal communication).
Effects ofoligonucleotides on cellproliferation/cytotoxicity
Cell proliferation/cytotoxicity was measured using the MUT
assay for each cell line after 24, 48 and 72 h growth in four
different concentrations (0.59AM, 1 AM, 5ILM, 10pM) of each
oligonucleotide. To a large extent the MT assays reflected
the microscopic appearances of the oligonucleotide-treated
cells. The OLlp53 oligonucleotides were non-specifically
toxic to all the cell lines regardess of TP53 status. The
toxicity was dose and duration dependent, with OLlp53s
generally being more toxic than OLlpS3rand, which was
more toxic than OLIp53as. There was some variation in this
pattern from one cell line to another. For example, OLlp53s
and OLlp53as seemed equally toxic to the cell lines Colo-
357, and CaPan-2 and OLlp53rand seemed more toxic than
OLlp53s and OLlp53as to the cell line AsPC-1. All the
OL1p53 oligonucleotides were considerably more toxic than
the Bip53 oligonucleotides.
The Bip53 oligonucleotides had a mild antiproliferative
effect at the highest concentration (10 9M), but this was
non-specific with respect to the oligonucleotide (Bip53as,
Bip53s and Bip53rand were equally toxic) and the cell line,
affecting them to approximately the same extent regardls of
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TP53 status. Respresentative MT[ results are shown in
Figure 2.
Effect ofoligonucleotides on pS3 expression in pancreatic cell
lines
Using the ELISA described, we were unable to detect p53
protein in the cell lines previously documented to lack p53
expression and also in the cell lines with only wild-type p53
expression (Barton et al., 1991; Ruggeri et al., 1992; Kalthoff
et al., 1993; Berrozpe et al. 1994). However, p53 was readily
detectable in cell lines expressing mutant p53 (PANC-1, FT45
and others), so all the ELISAs were performed on one of
these, FPT45. p53 protein levels were measured after 12, 24
and 48 h growth in the absence or presence of the antisense
and control oligonucleotides, at four different concentrations
(0.5pM, 1 9M, 5gtM, 10pAM) for the OL1p53 oligonucleotides,
and at seven different concentrations (0.5 gM, 1gM, 59AM,
10M, 20 M, 50pM and 100ILM) for the Bip53 oligo-
nucleotides. The calibration curve is shown in Figure 3 and
representative results in Figure 4.
No difference in p53 level was detectable 12, 24 or 48 h
after oligonucleotide was added, regardless of the oligo-
nucleotide added or the final oligonucleotide concentration,
even at high concentrations of Bip53 oligonucleotides. Since
the morpholocal effects of the OLlp53 oligonucleotides
were only apparent when cells were plated out directly into
the oligonucleotide-containing medium after trypsin/versene
treatment, we repeated the ELISA measurements on cells
pasaged in this manner and still observed no apparent effect
on p53 protein levels.
Effects ofoligomucleotides on in vitro transcription/translation
Using the plasmid pSP65p53 as template we analysed the
effects of different concentrations of oligonucleotide on in
vitro transcription/translation using the TNT coupled reti-
culocyte lysate system (Promega). In the absence of oligo-
nucleotide, p53 protein was readily produced, in addition to
a 46 kDa and other smaller protein products from alternative
internal initiation sites. Slightly less protein was produced
overall when any oligonucleotide was present in the reaction
mix. In addition, a dose-related inhibition of p53 protein
production (and smaler internally initiated proteins) was
apparent with the antisense oligonucleotide Bip53as but not
for its v&nwe and randomirti cntralc Riniq snnd RinvsrnnA
750 100 Suppression was detectable at 0.59M concentration and was
almost complete at a concentration of49AM (Figure 5). How-
ever, at 49AM concentration BipS3as also significantly
inhibited luciferase protein production (Figure 5) and slightly
inhibited AP2 protein production (Figure 6). Both these pro-
teins are encoded by genes to which BipS3as has no
significant complementarity.
The antisense oligonucleotide OLlpS3as and its controls
OLlp53s and OLlpS3rand all appeared to suppress p53 pro-
tein (and smaller intemally initiated proteins) production to
some extent. At a concentration of 0.59iM, OLlp53as
significntly suppressed and OLlp53rand completely sup-
pressed p53 protein production. At 1 9AM concentration p53
protein production was also markedly suppressed by
OLlp53s (Figure 7). However, the same effects were apparent
when luciferase or AP2 DNA was transcribed and translated
in the presence of these oligonucleotides (Figures 6 and
7).
1 10 100
p53 (ng ml-1)
1000
Figwe 3 Calibration curve for p53 ELISA. Serial dilutions of a
standard conomtration of p53 protein were froze in aliquots
and masured in duplicate on several ocasions. The rsults are
shown here with a linear and r ithmic scale. For dcarity,
error bars are omitted with th linear scale.
The phosphorothioate antisense oligonucleotide OLlp53as,
directed against exon 10 of p53 mRNA, failed to specifically
suppress p53 protein production in a cell-free assay system or
mutant p53 expression by pancreatic cancer cell lines growing
in vitro. In six different pancreatic cell lines, antiproliferative
effects were apparent at higher doses when the cells were
pretreated with versene/trypsin, but this was independent ofA3iaso dgolddes - Po
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Flgwe 4 Effect of different concentrations of oligonucleotides on p53 levels measured by ELISA using the cell line PT45. In the
range studied p53 levels were directly proportional to the absorbance at 492 nm. The results are shown here uncorrected for total
protein concentration. Therefore, p53 levels generally appear to rise because the cell number and hence total protein content of the
lysate steadily increases with time. Cell number and total protein concentrations were similar to untreated control cells except when
cells were plated directly into OLlp53s or OLlp53rand. In these instances, the cell number and total protein concentration (and
p53 concentration) of the lysate were proportionally less than similar cultures owing to the non-specific toxicity described in the
text. Corrected for total protein level, the p53 concentration was similar to that of untreated control cells. For clarity, error bars
are omitted from all but the 'no oligonucleotide' control curves.
p53 status (mutant, wild-type or absent), and in most cell
lines more dramatic antiproliferative effects were seen with
the control oligonucleotides OLlp53s and OLlp53rand.
These control oligonucleotides also appeared to affect
cell-cell or cell-substratum interactions after trypsin/versene
treatment at relatively low concentrations, causing the cells
to round up, clump together and lose attachment to the
culture dish.
These results, and particularly the results of the in vitro
transcription/translation experiments, strongly suggest that
the encouraging antiproliferative effects observed with
OLlp53as by other investigators are not due to a specific
antisense interaction leading to modulation of p53 expres-
sion. Fully phosphorothioate-substituted oligonucleotides are
now known to have undesirable features, notably a tendency
to non-specific toxicity owing to non-sequence-specific pro-
tein binding (including various growth factors, protein kinase
C and transcription factors, slow cellular uptake and activa-
tion of RNAse H at sites other than the main target sequence
(Stein and Krieg, 1994). Runs of four or more Gs in phos-
phorothioate oligonucleotides have also been documented to
produce non-specific growth inhibition independent of any
aniisense effect (Cohen, 1993; Stein and Krieg, 1994). For
this reason the OLlp53s control oligonucleotide could be
predicted to have more non-specific toxicity than OLlp53as,
but similar effects were observed with OLlp53rand, which
does not have runs of Gs.
Interestingly, a morphological phenomenon similar to that
seen with OLlp53s and OLlp53rand has been reported with
another unrelated phosphorothioate oligonucleotide
(Narayanan et al., 1992). Narayanan and co-workers used a
phosphorothioate 21-mer targeting the AUG initiation codon
of the DCC gene and found that the antisense oligonucleo-
tide but not the sense control resulted in a loss of adhesion to
the substratum. The cells reained viable but appeared
rounded up and detached from the substratum, and this
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Figure 5 Effects of Bip53 antisense oligonucleotide and controls
on p53 protein production by in vitro transcription translation.
The antisense oligonucleotide Bip53as suppresses p53 production
in a dose-related manner but also suppresses luciferase produc-
tion. Slight inhibition of p53 and luciferase protein synthesis is
seen at higher doses with both control oligonucleotides Bip53s
and Bip53rand. N. no DNA control; 0. no oligonucleotide; S.
Bip53s; A, Bip53as: R. Bip53rand.
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Fgure 6 Effects of Bip53 and OLlp53 antisense oligonucleotides
and controls on AP2 protein production by in vitro transcription
translation of the T7PAP2 expression plasmid. This plasmid has
the cDNA for transcription factor AP2 is cloned downstream of
a 17 promoter. All three OLlp53 oligonucleotides significantly
suppress protein production from this template and Bip53as
slightly suppresses protein production despite there being no
significant complementan'ty between any of these oligonucleotides
and the AP2 gene or T7 promoter. N, No DNA control; 0, no
oligonucleotide; S, sense control; A, antisense; R. randomer con-
trol; B, Bip53 oligonucleotides; 0 OLlp53 oligonucleotides.
effect was interpreted as being mediated through inhibition of
DCC expression, although DCC expression was not actually
measured. Whether or not this was the same effect that we
observed with our control phosphorothioate oligonucleotides
is purely speculative, but it is important to note that a subtle
difference in experimental technique (immediate exposure of
cells to an oligonucleotide versus exposure after attachment
to the substratum) can significantly affect the results of an
antisense experument.
There are other reasons for suspecting that the anti-
proliferative effects observed with OLlp53as in haemato-
poietic cells are unrelated to p53 expression. Exon 10, the
region targeted by OLlp53as. is well towards the 3' end of
p53 mRNA, and so any antisense effect is likely to be
mediated predominantly by RNAse H activation. Even if this
region of the mRNA is selectively and efficiently degraded by
Figure 7 Effects of OLlp53 antisense oligonucleotide and con-
trols on p53 protein production by in vitro transcription
translation. The OLlp53as oligonucleotide suppresses both p53
production and the production of luciferase protein to about the
same extent. The effect is dose related and apparent at a concen-
tration of 0.5 iLM. A more marked suppression of p53 and luci-
ferase synthesis is seen with the control oligonucleotide
OLlpS3rand and a less profound effect with the control oligo-
nucleotide OLlp53s. N. No DNA control: 0. no oligonucleotide;
S. OL1p53as; A. OLlp53as; R. OLlpS3rand.
RNAse H, by the time exon 10 is reached translation of the
p53 message is almost complete. It is possible that minimally
truncated p53 proteins which still contain the important
highly conserved regions and which retain significant wild-
type p53 activity might be produced. Furthermore, p53 pro-
tein detected in acute myeloid leukaemia (AML) blast cells is
usually wild type not mutant (Fenaux et al., 1991; Slinger-
land et al.. 1991; Sugimoto et at., 1991; Hu et al., 1992).
According to current models of p53 activity, a reduction in
expression of wild-type p53 would be predicted to result in
loss of growth control not growth suppression, as reported in
these experiments with haematopoietic cells.
The results of experiments using the chimaenrc phosphoro-
thioate-phosphodiester antisense oligonucleotide Bip53as,
directed against the p53 translation initiation codon, support
the contention that great care must be exercised in designing
and interpreting the results of antisense experiments. We
found that Bip53as did suppress p53 protein production by in
vitro transcription/translation but also suppressed protein
production from unrelated control luciferase and AP2 genes.
However, in a pancreatic cell line expressing mutant p53
there was no demonstrable suppression of p53 protein pro-
duction even at very high concentrations (100 M). A mild
non-specific antiproliferative effect was seen at higher concen-
trations similar to that seen with the control oligonucleotides
Bip53s and Bip53rand and regardless of the p53 status of the
cells. Although Bip53as has been reported to down-regulate
p53 expression in CML cells (Bi et al., 1994), our results
suggest that the expression of other genes might also be
modulated and (as for the OLlp53 oligonucleotides) that
these are not necessarily predictable on the basis of sequence
complementan'ty or homology with the oligonucleotide.
Interestingly, in the CML cells, suppression of p53 expression
using Bip53as stimulated colony formation and promoted
proliferation, supporting the notion that suppression of wild-
type p53 expression might be growth stimulatory in certain
circumstances (Bi et al., 1994).
Even if a perfect antisense oligonucleotide could be found
which only affected p53 expression, problems would remain
before antisense oligonucleotides against p53 could be con-
sidered a realistic option for patients with cancer. Even in
malignancies in which expression of mutant p53 with loss of
the wild-type allele predominates, effective suppression of
mutant p53 expression might be hazardous, for some mutant
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proteins retain important wild-type functions. Reduction in
expression of a mutant p53 protein by antisense interaction
has already been reported to enhance tumour cell prolifera-
tion and tumorigenicity of lung cancer cell lines (Mukho-
padhyay and Roth, 1993).
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